Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: A carrier includes a front portion with a first plurality of panels and a back portion with a second plurality of panels. The first plurality of panels at least partially surrounds a front interior space for receiving at least one container and includes a front panel, a front central panel, and at least one front side panel. The second plurality of panels at least partially surrounds a back interior space for receiving at least one container and includes a back panel, a back central panel, and at least one back side panel. The front central panel and the back central panel are separably connected at a line of weakening and are at least partially in face-to-face contact in a first configuration of the carrier, the carrier is positionable to a second configuration wherein the front portion and the back portion are at least partially separated at the line of weakening.

Abstract: A carton for containing at least one article. The carton includes a plurality of panels at least partially forming an interior of the carton. The plurality of panels includes a top panel. The carton includes an article protection flap foldably connected to at least one panel of the plurality of panels. The article protection flap is moveable between a first position that is substantially parallel to the top panel and a second position wherein the article protection flap is folded relative to the top panel. The at least one access feature in the top panel is for positioning the article protection flap from the first position to the second position.

Abstract: A carrier includes a front portion with a first plurality of panels and a back portion with a second plurality of panels. The first plurality of panels at least partially surrounds a front interior space for receiving at least one container and includes a front panel, a front central panel, and at least one front side panel. The second plurality of panels at least partially surrounds a back interior space for receiving at least one container and includes a back panel, a back central panel, and at least one back side panel. The front central panel and the back central panel are separably connected at a line of weakening and are at least partially in face-to-face contact in a first configuration of the carrier, the carrier is positionable to a second configuration wherein the front portion and the back portion are at least partially separated at the line of weakening.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: In a first aspect, the present disclosure provides a method for making an inorganic thermoset resin, the method comprising: (a) mixing SiO2, H2O and a metallic hydroxide for generating an alkaline aqueous solution with pH from 10 to 14 comprising a metallic silicate, wherein said metallic hydroxide generates a first metallic oxide in the aqueous solution, (b) adding aluminum oxide (Al2O3) and silicon oxide (SiO2) to the alkaline aqueous solution comprising a metallic silicate generated in step (a) and (c) adding halloysite nanotubes (Al2Si2O5(OH)4) to the solution generated in step (b). The present disclosure further provides an inorganic thermoset resin obtainable by the method as defined in the first aspect of the disclosure.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: A carrier for holding at least one container includes a plurality of panels extending at least partially around an interior space of the carrier and including a front panel, a back panel, at least one side panel, a first bottom panel, a second bottom panel, and at least one central panel. At least one divider flap extends from the at least one central panel to at least one of the front panel and the back panel. The first bottom panel includes at least one male locking feature and the second bottom panel includes at least one female locking feature for receiving the at least one male locking feature. The at least one male locking feature engages the at least one divider flap to lock the at least one divider flap in a generally perpendicular position relative to the central panel.

Abstract: A method for a curing cycle of an inorganic thermoset resin, the method comprising: (a) adding a hardener in a concentration from 18 to 30% by weight of the resin to said inorganic thermoset resin and (b) curing the resin at a temperature from 110 to 120° C. An inorganic thermoset resin, comprising a hardener in a concentration from 18 to 30% by weight of the resin. A vehicle interior panel, comprising a composite comprising a composite matrix of a natural fibre set within an inorganic thermoset resin.

Abstract: The invention relates to a feeding carriage for a compressor machine of the type having an upper filling end through which a particulate material which is to be compressed in a mold of the compressor machine is introduced, and a lower discharging end for discharging said particulate material towards said mold. At least some of the elements forming said feeding carriage can move with respect to one another, which thereby allows modifying the geometry of at least one of said lower discharging end, said upper filling end and an intermediate portion of the supply carriage located between both ends. The invention also relates to the use of such a feeding carriage comprising the initial steps of determining optimum carriage geometry for a particulate material which is to be compressed and applying said optimum carriage geometry to the feeding carriage.

Abstract: In a first aspect, the present disclosure provides a method for making an inorganic thermoset resin, the method comprising: (a) mixing SiO2, H2O and a metallic hydroxide for generating an alkaline aqueous solution with pH from 10 to 14 comprising a metallic silicate, wherein said metallic hydroxide generates a first metallic oxide in the aqueous solution, (b) adding aluminum oxide (Al2O3) and silicon oxide (SiO2) to the alkaline aqueous solution comprising a metallic silicate generated in step (a) and (c) adding halloysite nanotubes (Al2Si2O5(OH)4) to the solution generated in step (b). The present disclosure further provides an inorganic thermoset resin obtainable by the method as defined in the first aspect of the disclosure.

Abstract: In a first aspect, the present disclosure provides a method for making an inorganic thermoset resin, the method comprising: (a) mixing SiO2, H2O and a metallic hydroxide for generating an alkaline aqueous solution with pH from 10 to 14 comprising a metallic silicate, wherein said metallic hydroxide generates a first metallic oxide in the aqueous solution, (b) adding aluminum oxide (Al2O3) and silicon oxide (SiO2) to the alkaline aqueous solution comprising a metallic silicate generated in step (a) and (c) adding halloysite nanotubes (Al2Si2O5(OH)4) to the solution generated in step (b). The present disclosure further provides an inorganic thermoset resin obtainable by the method as defined in the first aspect of the disclosure.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: A carrier that is at least partially holding a plurality of containers. The carrier can include a plurality of panels comprising a bottom panel, a first side panel foldably connected to the bottom panel, a second side panel foldably connected to the bottom panel, a first top panel foldably connected to the first side panel, and a second top panel foldably connected to the second side panel. At least one container-receiving feature extends in at least the bottom panel. The at least one container-receiving feature can at least partially receive at least one container of the plurality of containers. At least one retention flap is foldably connected to the first top panel or the second top panel. The at least one retention flap engages at least a portion of a flange of at least one container.

Abstract: A carton for containing at least one article. The carton comprises a plurality of panels at least partially forming an interior of the carton. The plurality of panels comprises a top panel. The carton comprises an article protection flap foldably connected to at least one panel of the plurality of panels. The article protection flap is moveable between a first position that is substantially parallel to the top panel and a second position wherein the article protection flap is folded relative to the top panel. The at least one access feature in the top panel is for positioning the article protection flap from the first position to the second position.

Abstract: A carton for containing a plurality of articles. The carton comprises a plurality of panels that extends at least partially around an interior of the carton. The plurality of panels comprises a top panel, a bottom panel, a first side panel, and a second side panel. The carton comprises a first corner and a second corner at a closed end. The first corner has a first configuration and the second corner has a second configuration, the first configuration being different than the second configuration so that the first corner and second corner are asymmetrical.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.